Testing HR+ / HER2-patients with advanced or metastatic breast cancer for identification of tissue mutations in the PIK3CA gene: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO)

被引：0
|
作者：
Boutis, A. [1 ]
Nikolaou, M. [1 ]
Ardavanis, A. [1 ]
Tolis, C. [1 ]
Loga, K. [1 ]
Korantzis, I. [1 ]
Koumarianou, A. [1 ]
Christopoulou, A. N. [1 ]
Papatsimpas, G. [1 ]
Bokas, A. [1 ]
Pliarchopoulou, K. [1 ]
Kampletsas, E. [1 ]
Kesisis, G. [1 ]
Biziota, E. [1 ]
Psianou, K. [1 ]
Karageorgopoulou, S. [1 ]
Sogka, E. A. [1 ]
Tsoukalas, N. G. [1 ]
Chatzifoti, N. [1 ]
Saridaki-Zoras, Z. [1 ]
机构：
[1] Hellenic Soc Med Oncol, HeSMO, Athens, Greece
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.615
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
439P
引用
收藏
页码：S366 / S366
页数：1
相关论文
共 50 条
  • [41] PIK3CA registry: A noninterventional, descriptive, retrospective cohort study of PIK3CA mutations in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)
    Rajadurai, Pathmanathan
    Semiglazova, Tatiana
    Hegmane, Alinta
    El Karak, Fadi
    Chiu, Joanne W.
    Gupta, Sudeep
    Azim, Hamdy A.
    Kitzen, Josef Jem
    Arnaud, Antoine
    Haftchenary, Sina
    Wu, Jiwen
    Menon-Singh, Lakshmi
    Smith, LaTonya
    Zhukova, Lyudmila
    CANCER RESEARCH, 2022, 82 (04)
  • [42] Biomarker analysis in HR+, HER2-, locally advanced, or metastatic breast cancer patients treated with buparlisib: results from BELLE-3
    Solovieff, Nadia
    Wang, Ying A.
    Sankaran, Banu
    Scheuer, Nicolas
    El-Hashimy, Mona
    Weber, Denis
    Sellami, Dalila
    Di Leo, Angelo
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [43] Implications of somatic TP53 and PIK3CA mutations in patients with metastatic breast cancer who underwent germline BRCA testing
    Yam, Clinton
    Barrera, Angelica Gutierrez
    Huang, Davis
    Lin, Xinyi
    Litton, Jennifer K.
    Arun, Banu
    CANCER RESEARCH, 2018, 78 (04)
  • [44] PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study
    Guarneri, V.
    Dieci, M. V.
    Bisagni, G.
    Brandes, A. A.
    Frassoldati, A.
    Cavanna, L.
    Musolino, A.
    Giotta, F.
    Rimanti, A.
    Garrone, O.
    Bertone, E.
    Cagossi, K.
    Nanni, O.
    Piacentini, F.
    Orvieto, E.
    Curtarello, M.
    Chic, N.
    D'Amico, R.
    Prat, A.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S23 - S23
  • [45] The association between baseline patient characteristics and alpelisib-induced hyperglycaemia in patients with HR+, HER2-, PIK3CA-mutated metastatic breast cancer
    Godina, Eva
    Borstnar, Simona
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Characteristics of HR+/HER2-patients with recurrent disease by HER2 expression from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)
    Alvarez, Isabel
    Guerrero, Angel
    Lopez-Tarruella, Sara
    Martinez, Purificacion
    Mori, Marta
    Falo, Catalina
    Antolin, Silvia
    Rodriguez, Cesar A.
    Margeli, Mireia
    Garau, Isabel
    Tibau, Ariadna
    Moreno, Diana
    Cruz, Josefina
    Jose Echarri, Maria
    Anton, Antonio
    Rodriguez-Lescure, Alvaro
    Jose Escudero, Maria
    Bezares, Susana
    Rojo, Federico
    Jara, Carlos
    CANCER RESEARCH, 2021, 81 (04)
  • [47] Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2-Advanced Breast Cancer
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 : S13 - S14
  • [48] Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2-Advanced Breast Cancer
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 (SUPPL 1): : S13 - S14
  • [49] Association of PIK3CA mutations with efficacy in HER2-positive first-line metastatic breast cancer: a meta-analysis
    Swain, Sandra
    Cortes, Javier
    Xu, Binghe
    Lambertini, Chiara
    Essioux, Laurent
    Knott, Adam
    Restuccia, Eleonora
    Madjar, Katrin
    De Haas, Sanne Lysbet
    CANCER RESEARCH, 2023, 83 (05)
  • [50] Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2-Advanced Breast Cancer in the USA?
    Wu, Wenhua
    Lin, Huiting
    Cai, Jiaqin
    Sun, Hong
    Liu, Jia
    Hu, Congting
    Wei, Xiaoxia
    CLINICAL DRUG INVESTIGATION, 2023, 43 (12) : 939 - 948
12345